Tag: GlycoConnect
Beyond Random: Why Site-Specific Conjugation Is Redefining the ADC Therapeutic Window
Site-specific conjugation is reshaping how antibody-drug conjugates are engineered, replacing the structural heterogeneity of random conjugation with defined, homogeneous constructs. As multiple bioconjugation platforms...
Bristol Myers Squibb Enters Licensing Deal with Lonza for SYNtecan™ ADC...
Lonza, a global leader in contract development and manufacturing, has announced an exclusive single-target licensing agreement with Bristol Myers Squibb (BMS) for its proprietary SYNtecan™ linker-payload platform*. This agreement marks a significant milestone in advancing next-generation antibody-drug conjugate (ADC) therapeutics for oncology and other serious diseases.
Lonza Strengthens Advanced Synthesis Capabilities to Lead Bioconjugates Innovation and Development
Lonza Strengthens Advanced Synthesis Capabilities to Lead Bioconjugates Innovation and Development
Lonza’s Synaffix and BigHat Biosciences to Jointly Development an AI-Designed ADC
Following a series of successful initial preclinical proof of concept studies, Lonza's subsidiary Synaffix has licensed its antibody-drug conjugates (ADC-) technology to BigHat Biosciences. BigHat will combine...
Acquisition of Synaffix Strengthens Lonza’s Bioconjugates Offering
In a statement earlier today, Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, confirmed that it has acquired Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugates (ADCs).
South Korean Chong Kun Dang Pharm Licenses Synaffix Platform Technology
South Korean's Chong Kun Dang Pharm (CKD) has entered a licensing agreement with Netherlands-based Synaffix for the development of novel antibody-drug conjugates (ADCs) with best-in-class therapeutic index.
Amgen and Synafix Sign US $2 Billion License Agreement
Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), confirmed that it had signed...
Emergence Therapeutics Becomes the 10th Company to License Synaffix’ ADC Platform...
In a statement earlier today, Dutch-biotech Synaffix and German Emergence Therapeutics announced that the Companies have entered into a licensing agreement of up to...
Kyowa Kirin Expands License Agreement with Synaffix
Japanese pharmaceutical and biotechnology company Kyowa Kirin has expanded its license agreement with The Netherlands based Synaffix with one new antibody-drug conjugates (ADC) target added to...
Mersana Therapeutics and Janssen Biotech Sign Agreement to Advance Novel Antibody-Drug...
Mersana Therapeutics has signed a research collaboration and license agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to...
